OTC nasal spray seemed to cut COVID infections by 67% in mid-sized trial
The Phase 2 trial is not definitive, but it comes as vaccine access is severely restricted.
https://arstechnica.com/health/2025/09/otc-nasal-spray-seemed-to-cut-covid-infections-by-67-in-mid-sized-trial/?utm_brand=arstechnica&utm_social-type=owned&utm_source=mastodon&utm_medium=social
@arstechnica
- the intendwd treatment was azelastine nasal spray three times per day.
- "In the intention-to-treat (ITT) population, the incidence of PCR-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group (n = 5 [2.2%]) compared with the placebo group (n = 15 [6.7%]) (OR, 0.31; 95% CI, 0.11-0.87)."
- https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2838335
- the intendwd treatment was azelastine nasal spray three times per day.
- "In the intention-to-treat (ITT) population, the incidence of PCR-confirmed SARS-CoV-2 infection was significantly lower in the azelastine group (n = 5 [2.2%]) compared with the placebo group (n = 15 [6.7%]) (OR, 0.31; 95% CI, 0.11-0.87)."
- https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2838335